High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.

Based on the high incidence of thromboembolic events (TEs) observed in lung adenocarcinomas with ALK translocations and taking into account the biological proximity of ROS1 and ALK, we conducted a retrospective analysis of patients with advanced lung carcinoma carrying rearrangements in ROS1 from 23 centres in Spain and one centre in Portugal. The main objective of the study was to analyse the incidence of TE in this population, looking for predictive risk factors, and its impact on overall survival. A total of 58 patients were included. The incidence of TEs throughout the disease was 46.6% (n = 27) with a median follow-up of 19 months (range: 1-78 months) and a median overall survival of 52 months in the total population and 50 months for the patients presenting TEs, with a hazards ratio of 1.12 (95% confidence interval: 0.47-2.65) p = 0.78. The majority of the events were venous (n = 24; 89%) and occurred in the ambulatory setting (n = 18; 67%). Almost half of the patients (n = 13; 48%) presented the TE in the peri-diagnostic period. The high incidence of thrombosis, especially during the cancer diagnosis process, requires special attention from a clinician. Despite the limitations of such a small descriptive study, its results are in accordance with previously reported data. It would be important to design prospective studies of antithrombotic prophylaxis in this population because of their possible impact in reducing the risk of TEs.

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement Dr. Muñoz reports grants, personal fees, and non-financial support from Sanofi and Celgene; personal fees and non-financial support from Roche and Amgen; grants and personal fees from Leo Pharma; personal fees from AstraZeneca, Servier, Pfizer, Daiichi Sankyo, Bayer, Halozyme, Rovi, Merck Sharp & Dohme, and Lilly; and non-financial support from Merck Serono. Dr. Aguado reports personal fees and non-financial support from ROCHE; personal fees from AstraZeneca, Boehringer, Sanofi, Pierre Fabre, MSD, BMS; and non-financial support from Novartis. Dr. Oliveira reports grants from AstraZeneca and personal fees from Roche, Pierre Fabre, and Bristol-Myers Squibb. Dr. Zugazagoitia reports personal fees from Guardant Health, NanoString, Roche, and Pfizer. Dr. Ortega reports personal fees and non-financial support from Sanofi, Amgen, and Leo Pharma and non-financial support from Roche. Dr. Carmona reports personal fees from Rovi and Leo Pharma. Dr. Domine reports personal fees from AstraZeneca, BMS, Boehringer Ingelheim, MSD, Pfizer, and Roche. Dr. Biosca reports personal fees and other from Leo Pharma, Sanofi, and Rovi. Dr. Juan-Vidal reports personal fees from Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche/Genetech, AstraZeneca, Pfizer, Eli Lilly, Abbvie, and Takkeda. Dr. Paz-Ares reports grants and personal fees from BMS and AstraZeneca and personal fees from MSD, Roche, Lilly, Merck, Novartis, Angem, Incyte, Takeda, Blueprint, and Bayer. Dr. Ponce-Aix reports personal fees and others from MSD, AstraZeneca, BMS, Pharmamar, Roche, Boehringer, Lilly, and Merck. Dr. Calvo reports honoraria as the speaker and consultant on advisory boards from Roche, BMS, MSD, Pfizer, Lilly, Astra-Zeneca, Boehringer, Novartis, and Takeda. The rest of the authors declare no conflicts of interest.